Best Practice & Research Clinical Rheumatology
Volume 20, Issue 3 , Pages 487-505 , June 2006

Uveitis

  • Santiago Muñoz-Fernández, MD, PhD (Professor of Medicine)

      Affiliations

    • Corresponding Author InformationCorresponding author. Address: Servicio de Reumatología, Hospital Universitario La Pas, Paseo de la Castellana 261, 28046 Madrid, Spain. Tel.: +34 91 7277193; fax: +34 91 7292794.
    • ,
  • Emilio Martín-Mola, MD, PhD (Professor of Medicine)

References 

  1. Bloch-Michel E, Nussenblatt RB. International uveitis study group recommendations for the evaluation of intraocular inflammatory disease. American Journal of Ophthalmology. 1987;103:234–235
  2. Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California epidemiology of uveitis study. Ophthalmology. 2004;111:491–500
  3. Bodaghi B, Cassoux N, Wechsler B, et al. Chronic severe uveitis: etiology and visual outcome in 927 patients from a single center. Medicine (Baltimore). 2001;80:263–270
  4. McCannel CA, Holland GN, Helm CJ, et al. Causes of uveitis in the general practice of ophthalmology. UCLA community-based uveitis study group. American Journal of Ophthalmology. 1996;121:35–46
  5. Banares A, Jover JA, Fernandez-Gutierrez B, et al. Patterns of uveitis as a guide in making rheumatologic and immunologic diagnoses. Arthritis and Rheumatism. 1997;40:358–370
  6. Edmunds L, Elswood J, Calin A. New light on uveitis in ankylosing spondylitis. The Journal of Rheumatology. 1991;18:50–52
  7. Banares A, Hernandez-Garcia C, Fernandez-Gutierrez B, Jover JA. Eye involvement in the spondyloarthropathies. Rheumatic Diseases Clinics of North America. 1998;24:771–784
  8. Fernandez-Melon J, Munoz-Fernandez S, Hidalgo V, et al. Uveitis as the initial clinical manifestation in patients with spondyloarthropathies. The Journal of Rheumatology. 2004;31:524–527
  9. Chang JH, McCluskey PJ, Wakefield D. Acute anterior uveitis and HLA-B27. Survey of Ophthalmology. 2005;50:364–388
  10. Linssen A, Rothova A, Valkenburg HA, et al. The lifetime cumulative incidence of acute anterior uveitis in a normal population and its relation to ankylosing spondylitis and histocompatibility antigen HLA-B27. Investigative Ophthalmology and Visual Science. 1991;32:2568–2578
  11. Careless DJ, Inman RD. Acute anterior uveitis: clinical and experimental aspects. Seminars in Arthritis and Rheumatism. 1995;24:432–441
  12. Feltkamp TE. Ophthalmological significance of HLA associated uveitis. Eye. 1990;4:839–844
  13. Hammer RE, Maika SE, Richardson JA, et al. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27 associated human disorders. Cell. 1990;63:1099–1112
  14. Khare SD, Luthra HS, David CS. Spontaneous inflammatory arthritis in HLA-B27 transgenic mice lacking β2-microglobulin: a model of human spondyloarthropathies. The Journal of Experimental Medicine. 1995;182:1153–1158
  15. Monowarul Islam SM, Numaga J, Fujino Y, et al. HLA-DR8 and acute anterior uveitis in ankylosing spondylitis. Arthritis and Rheumatism. 1995;38:547–550
  16. Maksymowych WP, Russell AS. Polymorphism in the LMP2 gene influences the relative risk for acute anterior uveitis in unselected patients with ankylosing spondylitis. Clinical and Investigative Medicine. 1995;18:42–46
  17. Rosenbaum JT, McDevitt HO, Guss RB, Egbert PR. Endotoxin-induced uveitis in rats as a model for human disease. Nature. 1980;286:611–613
  18. Baggia S, Lyons JL, Angell E, et al. A novel model of bacterially induced acute anterior uveitis in rats and the lack of effect from HLA-B27 expression. Journal of Investigative Medicine. 1997;45:295–301
  19. Bañares A, Jover JA, Fernández-Gutierrez B, et al. Bowel inflammation in anterior uveitis and spondyloarthropathy. The Journal of Rheumatology. 1995;22:1112–1127
  20. Maksymowych W. Etiology and pathogenesis of ankylosing spondylitis. In:  Hochberg MC,  Silman AJ,  Smolen JS,  Weinblatt ME,  Weisman MH editor. Rheumatology. 3rd edn. St Louis: Mosby; 2003;p. 1183–1192
  21. Rosembaun JT. An algorithm for the systemic evaluation of patients with uveitis: guidelines for the consultant. Seminars in Arthritis and Rheumatism. 1990;19:248–257
  22. Bonilla G, Muñoz-Fernández S, Hidalgo V, et al. Validate of the efficiency of the application of a diagnostic protocol based on the patterns of presentation of uveitis. Arthritis and Rheumatism. 2001;44(supplement):S123;[abstract]
  23. Fernández-Melón J, Muñoz-Fernández S, Hidalgo V, et al. Utility of a multidisciplinary unit of uveitis. Annals of the Rheumatic Diseases. 2002;61(supplement):303;[abstract]
  24. Dougados M, Berenbaum F, Maetzel A, Amor B. Prévention des épides d'uvéite antérieure aiguë des spondylarthropathies par la salazosulfapyridine. Revue du Rhumatisme. 1993;60:81–83
  25. Benitez-del-Castillo JM, García-Sánchez J, Iradier T, Bañares A. Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye. 2000;14:340–343
  26. Munoz-Fernandez S, Hidalgo V, Fernandez-Melon J, et al. Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period. The Journal of Rheumatology. 2003;30:1277–1279
  27. Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis and Rheumatism. 2005;52:2447–2451
  28. Becker MD, Smith JR, Max R, Fiehn C. Management of sight-threatening uveitis. New therapeutic options. Drugs. 2005;65:497–519
  29. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. American Journal of Ophthalmology. 2000;130:492–513
  30. BenEzra D, Cohen E, Chajek T, et al. Evaluation of conventional therapy versus cyclosporine A in Behcet's syndrome. Transplantation Proceedings. 1988;20:136–143
  31. Nussenblatt RB, de Smet MD, Rubin B, et al. A masked, randomized, dose–response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin. American Journal of Ophthalmology. 1993;115:583–591
  32. Nussenblatt RB, Palestine AG, Chan CC, et al. Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. American Journal of Ophthalmology. 1991;112:138–146
  33. Nussenblatt RB, Palestine AG, Chan CC. Cyclosporine therapy for uveitis: long-term followup. Journal of Ocular Pharmacology and Therapeutics. 1985;1:369–382
  34. Vitale AT, Rodriguez A, Foster CS. Low-dose cyclosporin A therapy in treating chronic, noninfectious uveitis. Ophthalmology. 1996;103:365–373
  35. de Vries J, Baarsma GS, Zaal MJ, et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. British Journal of Ophthalmology. 1990;74:344–349
  36. Mathews JD, Crawford BA, Bignell JL, Mackay IR. Azathioprine in active chronic iridocyclitis. A double-blind controlled trial. British Journal of Ophthalmology. 1969;53:327–330
  37. Yazici H, Pazarli H, Barnes CG, et al. controlled trial of azathioprine in Behcet's syndrome. The New England Journal of Medicine. 1990;322:281–285
  38. Samson CM, Waheed N, Baltatzis S, Foster CS. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology. 2001;108:1134–1139
  39. Mochizuki M, Masuda K, Sakane T, et al. A clinical trial of FK506 in refractory uveitis. American Journal of Ophthalmology. 1993;115:763–769
  40. Shanmuganathan VA, Casely EM, Raj D, et al. The efficacy of sirolimus in the treatment of patients with refractory uveitis. British Journal of Ophthalmology. 2005;89:666–669
  41. Baltatzis S, Tufail F, Yu EN, et al. Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders. Ophthalmology. 2003;110:1061–1065
  42. Goldstein DA, Fontanilla FA, Kaul S, et al. Long-term follow-up of patients treated with short-term high-dose chlorambucil for sight-threatening ocular inflammation. Ophthalmology. 2002;109:370–377
  43. Nussenblatt RB, Fortin E, Schiffman R, et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proceedings of the National Academy of Sciences of the United States of America. 1999;96:7462–7466
  44. Rosenbaum JT, George RK, Gordon C. The treatment of refractory uveitis with intravenous immunoglobulin. American Journal of Ophthalmology. 1999;127:545–549
  45. Demiroglu H, Ozcebe OI, Barista I, et al. Interferon alfa-2b, colchicine, and benzathine penicillin versus colchicine and benzathine penicillin in Behcet's disease: a randomised trial. Lancet. 2000;355:605–609
  46. Dick AD, Meyer P, James T, et al. Campath-1H therapy in refractory ocular inflammatory disease. British Journal of Ophthalmology. 2000;84:107–109
  47. Sfikakis PP, Kaklamanis PH, Elezoglou A, et al. Infliximab for recurrent, sight-threatening ocular inflammation in adamantiades-behcet disease. Annals of Internal Medicine. 2004;140:404–406
  48. Foster CS, Tufail F, Waheed NK, et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Archives of Ophthalmology. 2003;121:437–440
  49. Smith JA, Thompson DJ, Whitcup SM, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Care Research. 2005;53:18–23

PII: S1521-6942(06)00038-6

doi: 10.1016/j.berh.2006.03.008

Best Practice & Research Clinical Rheumatology
Volume 20, Issue 3 , Pages 487-505 , June 2006

Article Tools

* Image Usage & Resolution